Emerging paradigms in nanostructured targeted drug delivery systems

Nanostructured drug delivery systems have emerged as powerful and versatile approaches to overcome the limitations of conventional therapeutic strategies, including poor bioavailability, non-specific distribution, and dose-limiting toxicity. By enabling precise control over particle size, surface characteristics, drug loading, and release kinetics, nanocarriers offer enhanced pharmacokinetic and pharmacodynamic performance, along with improved therapeutic specificity. This comprehensive review critically examines emerging paradigms in Nanostructured drug delivery systems, with a particular focus on design strategies, surface functionalization, and translational potential for targeted therapeutics. The review systematically discusses the fundamental principles governing nanocarrier behavior, including physicochemical characteristics, nano–bio interactions, and pharmacokinetic considerations. Various classes of Nanostructured drug delivery systems—such as lipid-based, polymeric, inorganic, carbon-based, and biomimetic carriers—are evaluated with respect to their design rationale, advantages, and limitations. Advanced targeting strategies, including passive and active targeting, ligand-based functionalization, and stealth modifications, are highlighted for their role in enhancing site-specific delivery and therapeutic efficacy. Furthermore, the review explores cellular uptake mechanisms, intracellular trafficking, and subcellular targeting, providing insights into how nanocarriers can be engineered to overcome biological barriers. The translational landscape of nanomedicine is critically assessed, addressing preclinical evaluation, clinical development, manufacturing scalability, regulatory challenges, and safety considerations. Emerging trends, such as artificial intelligence–assisted nanocarrier design, stimuli-responsive systems, bioinspired platforms, and personalized nanomedicine, are also discussed as future directions. In summary, this review underscores the significant progress and remaining challenges in the field of Nanostructured drug delivery systems and highlights their transformative potential in advancing targeted therapeutics and precision medicine.